TCM
PDLI

Tributary Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Tributary Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-382,731
Closed -$3.18M – 180
2014
Q1 		$3.18M Hold
382,731
– – 0.67% 80
2013
Q4 		$3.23M Buy
382,731
+9,777
+3% +$82.4K 0.64% 71
2013
Q3 		$2.97M Buy
372,954
+88,170
+31% +$709K 0.61% 75
2013
Q2 		$2.2M Buy
+284,784
New +$2.22M 0.36% 136

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tributary Capital Management's PDLI Position: Q2 2014 in Review

Tributary Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2014, closing a stake of 382,731 shares — an estimated $3.18M sold.

Tributary Capital Management first reported a position in PDLI in Q2 2013 and held it in 4 quarters. The position peaked at $3.23M in Q4 2013. 222 funds tracked by Wall St. Rank hold PDLI as of Q2 2014.

  • Tributary Capital Management reported no remaining PDL BioPharma, Inc. position as of Q2 2014 after selling out during the quarter.
  • Tributary Capital Management sold 382,731 PDL BioPharma, Inc. shares in Q2 2014, an estimated $3.18M.
  • Tributary Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 4 quarters.
  • Tributary Capital Management's PDL BioPharma, Inc. position peaked at $3.23M in Q4 2013.
  • 222 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2014.

Based on Tributary Capital Management's 13F filing for Q2 2014, filed 4 Aug 2014.